Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,885

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

The Influence of Probiotics on the Firmicutes/Bacteroidetes Ratio in the Treatment of Obesity and Inflammatory Bowel disease

Open access
Stojanov, Spase, Berlec, Aleš, Štrukelj, Borut·2020·Microorganisms
DOI 10.3390/microorganisms8111715
Open this paper in CoChat — free account

Abstract

The two most important bacterial phyla in the gastrointestinal tract, Firmicutes and Bacteroidetes, have gained much attention in recent years. The Firmicutes/Bacteroidetes (F/B) ratio is widely accepted to have an important influence in maintaining normal intestinal homeostasis. Increased or decreased F/B ratio is regarded as dysbiosis, whereby the former is usually observed with obesity, and the latter with inflammatory bowel disease (IBD). Probiotics as live microorganisms can confer health benefits to the host when administered in adequate amounts. There is considerable evidence of their nutritional and immunosuppressive properties including reports that elucidate the association of probiotics with the F/B ratio, obesity, and IBD. Orally administered probiotics can contribute to the restoration of dysbiotic microbiota and to the prevention of obesity or IBD. However, as the effects of different probiotics on the F/B ratio differ, selecting the appropriate species or mixture is crucial. The most commonly tested probiotics for modifying the F/B ratio and treating obesity and IBD are from the genus Lactobacillus. In this paper, we review the effects of probiotics on the F/B ratio that lead to weight loss or immunosuppression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/microorganisms8111715

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Research works printed but not linked: 83

  1. Thursby, 2017, Introduction to the human gut microbiota, Biochem. J., 474, 1823, 10.1042/BCJ20160510 · DOI · Paper page
  2. Montalto, 2009, Intestinal microbiota and its functions, Dig. Liver. Dis., 3, 30
  3. Arumugam, 2011, Enterotypes of the human gut microbiome, Nature, 473, 174, 10.1038/nature09944 · DOI · Paper page
  4. Seong, 2018, Taxonomic hierarchy of the phylum Firmicutes and novel Firmicutes species originated from various environments in Korea, J. Microbiol., 56, 1, 10.1007/s12275-018-7318-x · DOI
  5. Gibiino, 2018, Exploring Bacteroidetes: Metabolic key points and immunological tricks of our gut commensals, Dig. Liver. Dis., 50, 635, 10.1016/j.dld.2018.03.016 · DOI
  6. Shin, 2015, Proteobacteria: microbial signature of dysbiosis in gut microbiota, Trends Biotechnol., 33, 496, 10.1016/j.tibtech.2015.06.011 · DOI · Paper page
  7. Morgan, 2012, Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment, Genome Biol., 13, R79, 10.1186/gb-2012-13-9-r79 · DOI · Paper page
  8. Gagliardi, A., Totino, V., Cacciotti, F., Iebba, V., Neroni, B., Bonfiglio, G., Trancassini, M., Passariello, C., Pantanella, F., and Schippa, S. (2018). Rebuilding the gut microbiota ecosystem. Int. J. Environ. Res. Public Health, 15. · DOI · Paper page
  9. Stojanov, 2020, Gut Microbiota and the metabolism of phytoestrogens, Rev. Bras. Farmacogn., 30, 145, 10.1007/s43450-020-00049-x · DOI
  10. Lazar, 2019, Gut microbiota, host organism, and diet trialogue in diabetes and obesity, Front. Nutr., 6, 21, 10.3389/fnut.2019.00021 · DOI
  11. Hruby, 2015, The epidemiology of obesity: A big picture, Pharmacoeconomics, 33, 673, 10.1007/s40273-014-0243-x · DOI
  12. Mitev, 2019, Association between the gut microbiota and obesity, Open Access Maced. J. Med. Sci., 7, 2050, 10.3889/oamjms.2019.586 · DOI
  13. Kimura, 2013, The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43, Nat. Commun., 4, 1829, 10.1038/ncomms2852 · DOI · Paper page
  14. Tseng, 2019, The gut microbiome in obesity, J. Formos. Med. Assoc., 118, S3, 10.1016/j.jfma.2018.07.009 · DOI
  15. Jiao, 2015, Farnesoid X receptor: a master regulator of hepatic triglyceride and glucose homeostasis, Acta Pharmacol. Sin., 36, 44, 10.1038/aps.2014.116 · DOI
  16. Barathikannan, K., Chelliah, R., Rubab, M., Daliri, E.B., Elahi, F., Kim, D.H., Agastian, P., Oh, S.Y., and Oh, D.H. (2019). Gut microbiome modulation based on probiotic application for anti-obesity: A review on efficacy and validation. Microorganisms, 7. · DOI
  17. Clarke, 2012, The gut microbiota and its relationship to diet and obesity: new insights, Gut Microbes, 3, 186, 10.4161/gmic.20168 · DOI · Paper page
  18. Crovesy, 2020, Profile of the gut microbiota of adults with obesity: a systematic review, Eur. J. Clin. Nutr., 74, 1251, 10.1038/s41430-020-0607-6 · DOI
  19. Kasai, C., Sugimoto, K., Moritani, I., Tanaka, J., Oya, Y., Inoue, H., Tameda, M., Shiraki, K., Ito, M., and Takei, Y. (2015). Comparison of the gut microbiota composition between obese and non-obese individuals in a Japanese population, as analyzed by terminal restriction fragment length polymorphism and next-generation sequencing. BMC Gastroenterol., 15. · DOI · Paper page
  20. Sohail, M.U., Elrayess, M.A., Al Thani, A.A., Al-Asmakh, M., and Yassine, H.M. (2019). Profiling the oral microbiome and plasma biochemistry of obese hyperglycemic subjects in Qatar. Microorganisms, 7. · DOI
  21. Xu, P., Li, M., Zhang, J., and Zhang, T. (2012). Correlation of intestinal microbiota with overweight and obesity in Kazakh school children. BMC Microbiol., 12. · DOI
  22. Bervoets, 2013, Differences in gut microbiota composition between obese and lean children: a cross-sectional study, Gut Pathog., 5, 10, 10.1186/1757-4749-5-10 · DOI · Paper page
  23. Hu, H.J., Park, S.G., Jang, H.B., Choi, M.K., Park, K.H., Kang, J.H., Park, S.I., Lee, H.J., and Cho, S.H. (2015). Obesity alters the microbial community profile in Korean adolescents. PLoS ONE, 10. · DOI
  24. Shoeib, 2011, Frequency of Firmicutes and Bacteroidetes in gut microbiota in obese and normal weight Egyptian children and adults, Arch. Med. Sci., 7, 501
  25. Vaiserman, A., Romanenko, M., Piven, L., Moseiko, V., Lushchak, O., Kryzhanovska, N., Guryanov, V., and Koliada, A. (2020). differences in the gut Firmicutes to Bacteroidetes ratio across age groups in healthy Ukrainian population. BMC Microbiol., 20. · DOI
  26. Castaner, 2018, The gut microbiome profile in obesity: A systematic review, Int. J. Endocrinol., 2018, 4095789
  27. Ze, 2012, Ruminococcus bromii is a keystone species for the degradation of resistant starch in the human colon, ISME J., 6, 1535, 10.1038/ismej.2012.4 · DOI · Paper page
  28. Flint, 2012, Microbial degradation of complex carbohydrates in the gut, Gut Microbes, 3, 289, 10.4161/gmic.19897 · DOI · Paper page
  29. Ji, 2012, Modulation of the murine microbiome with a concomitant anti-obesity effect by Lactobacillus rhamnosus GG and Lactobacillus sakei NR28, Benef. Microbes, 3, 13, 10.3920/BM2011.0046 · DOI
  30. Ji, 2018, Modulation of active gut microbiota by Lactobacillus rhamnosus GG in a diet induced obesity murine model, Front. Microbiol., 9, 710, 10.3389/fmicb.2018.00710 · DOI
  31. Chen, D., Yang, Z., Chen, X., Huang, Y., Yin, B., Guo, F., Zhao, H., Zhao, T., Qu, H., and Huang, J. (2014). The effect of Lactobacillus rhamnosus hsryfm 1301 on the intestinal microbiota of a hyperlipidemic rat model. BMC Complement. Altern. Med., 14. · DOI
  32. Thiennimitr, 2018, Lactobacillus paracasei HII01, xylooligosaccharides, and synbiotics reduce gut disturbance in obese rats, Nutrition, 54, 40, 10.1016/j.nut.2018.03.005 · DOI
  33. Murphy, 2013, Divergent metabolic outcomes arising from targeted manipulation of the gut microbiota in diet-induced obesity, Gut, 62, 220, 10.1136/gutjnl-2011-300705 · DOI
  34. Larsen, 2013, Effect of Lactobacillus salivarius Ls-33 on fecal microbiota in obese adolescents, Clin. Nutr., 32, 935, 10.1016/j.clnu.2013.02.007 · DOI
  35. Wang, 2019, Bacillus amyloliquefaciens SC06 protects mice against high-fat diet-induced obesity and liver injury via regulating host metabolism and gut microbiota, Front. Microbiol., 10, 1161, 10.3389/fmicb.2019.01161 · DOI
  36. Everard, 2014, Saccharomyces boulardii administration changes gut microbiota and reduces hepatic steatosis, low-grade inflammation, and fat mass in obese and type 2 diabetic db/db mice, mBio, 5, e01011, 10.1128/mBio.01011-14 · DOI
  37. Yu, 2017, Saccharomyces boulardii administration changes gut microbiota and attenuates D-galactosamine-induced liver injury, Sci. Rep., 7, 1359, 10.1038/s41598-017-01271-9 · DOI
  38. Kadooka, 2010, Regulation of abdominal adiposity by probiotics (Lactobacillus gasseri SBT2055) in adults with obese tendencies in a randomized controlled trial, Eur. J. Clin. Nutr., 64, 636, 10.1038/ejcn.2010.19 · DOI · Paper page
  39. Million, 2012, Obesity-associated gut microbiota is enriched in Lactobacillus reuteri and depleted in Bifidobacterium animalis and Methanobrevibacter smithii, Int. J. Obes., 36, 817, 10.1038/ijo.2011.153 · DOI
  40. Yin, 2010, Effects of four bifidobacteria on obesity in high-fat diet induced rats, World. J. Gastroenterol., 16, 3394, 10.3748/wjg.v16.i27.3394 · DOI
  41. Brusaferro, A., Cozzali, R., Orabona, C., Biscarini, A., Farinelli, E., Cavalli, E., Grohmann, U., Principi, N., and Esposito, S. (2018). Is it time to use probiotics to prevent or treat obesity?. Nutrients, 10. · DOI
  42. Mazloom, K., Siddiqi, I., and Covasa, M. (2019). Probiotics: How effective are they in the fight against obesity?. Nutrients, 11. · DOI
  43. Wicinski, M., Gebalski, J., Golebiewski, J., and Malinowski, B. (2020). Probiotics for the treatment of overweight and obesity in humans-a review of clinical trials. Microorganisms, 8. · DOI
  44. Fakhoury, 2014, Inflammatory bowel disease: clinical aspects and treatments, J. Inflamm. Res., 7, 113, 10.2147/JIR.S65979 · DOI · Paper page
  45. Pache, 2009, TNF-alpha blockers in inflammatory bowel diseases: practical consensus recommendations and a user’s guide, Swiss Med. Wkly., 139, 278
  46. Adegbola, S.O., Sahnan, K., Warusavitarne, J., Hart, A., and Tozer, P. (2018). Anti-TNF therapy in Crohn’s disease. Int. J. Mol. Sci., 19. · DOI
  47. Lu, 2018, Toll-like receptors and inflammatory bowel disease, Front. Immunol., 9, 72, 10.3389/fimmu.2018.00072 · DOI · Paper page
  48. Moossavi, 2013, Toll-like receptor signalling and their therapeutic targeting in colorectal cancer, Int. Immunopharmacol., 16, 199, 10.1016/j.intimp.2013.03.017 · DOI
  49. Motoi, 2014, Lipopeptides are signaled by Toll-like receptor 1, 2 and 6 in endolysosomes, Int. Immunol., 26, 563, 10.1093/intimm/dxu054 · DOI
  50. Kawasaki, 2014, Toll-like receptor signaling pathways, Front. Immunol., 5, 461, 10.3389/fimmu.2014.00461 · DOI · Paper page
  51. Kordjazy, 2018, Role of toll-like receptors in inflammatory bowel disease, Pharmacol. Res., 129, 204, 10.1016/j.phrs.2017.11.017 · DOI
  52. Mortha, 2014, Microbiota-dependent crosstalk between macrophages and ILC3 promotes intestinal homeostasis, Science, 343, 1249288, 10.1126/science.1249288 · DOI · Paper page
  53. Sun, 2018, Microbiota-derived short-chain fatty acids promote Th1 cell IL-10 production to maintain intestinal homeostasis, Nat. Commun., 9, 3555, 10.1038/s41467-018-05901-2 · DOI · Paper page
  54. Chakraborti, S., Chakraborti, T., Chattopadhyay, D., and Shaha, C. (2019). Role of gut microbiota in combating oxidative stress. Oxidative Stress in Microbial Diseases, Springer. · DOI
  55. Gophna, 2006, Differences between tissue-associated intestinal microfloras of patients with Crohn’s disease and ulcerative colitis, J. Clin. Microbiol., 44, 4136, 10.1128/JCM.01004-06 · DOI
  56. Prosberg, 2019, Increased abundance of proteobacteria in aggressive Crohn’s disease seven years after diagnosis, Sci. Rep., 9, 13473, 10.1038/s41598-019-49833-3 · DOI
  57. Sokol, 2008, Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients, Proc. Natl. Acad. Sci. USA, 105, 16731, 10.1073/pnas.0804812105 · DOI · Paper page
  58. Walker, A.W., Sanderson, J.D., Churcher, C., Parkes, G.C., Hudspith, B.N., Rayment, N., Brostoff, J., Parkhill, J., Dougan, G., and Petrovska, L. (2011). High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease. BMC Microbiol., 11. · DOI · Paper page
  59. Kabeerdoss, 2015, Alterations of mucosal microbiota in the colon of patients with inflammatory bowel disease revealed by real time polymerase chain reaction amplification of 16S ribosomal ribonucleic acid, Indian J. Med. Res., 142, 23, 10.4103/0971-5916.162091 · DOI
  60. Andoh, 2012, Multicenter analysis of fecal microbiota profiles in Japanese patients with Crohn’s disease, J. Gastroenterol., 47, 1298, 10.1007/s00535-012-0605-0 · DOI
  61. Andoh, 2007, Terminal restriction fragment length polymorphism analysis of the diversity of fecal microbiota in patients with ulcerative colitis, Inflamm. Bowel. Dis., 13, 955, 10.1002/ibd.20151 · DOI · Paper page
  62. Bloom, 2011, Commensal Bacteroides species induce colitis in host-genotype-specific fashion in a mouse model of inflammatory bowel disease, Cell Host Microbe, 9, 390, 10.1016/j.chom.2011.04.009 · DOI · Paper page
  63. Lo Sasso, G., Khachatryan, L., Kondylis, A., Battey, J.N.D., Sierro, N., Danilova, N.A., Grigoryeva, T.V., Markelova, M.I., Khusnutdinova, D.R., and Laikov, A.V. (2020). Inflammatory bowel disease-associated changes in the cut: Focus on Kazan patients. Inflamm. Bowel. Dis. · DOI
  64. Nemoto, 2012, Reduced diversity and imbalance of fecal microbiota in patients with ulcerative colitis, Dig. Dis. Sci., 57, 2955, 10.1007/s10620-012-2236-y · DOI
  65. Willing, 2010, A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes, Gastroenterology, 139, 1844, 10.1053/j.gastro.2010.08.049 · DOI · Paper page
  66. Liu, 2019, Lactobacillus reuteri DSM 17938 feeding of healthy newborn mice regulates immune responses while modulating gut microbiota and boosting beneficial metabolites, Am. J. Physiol. Gastrointest. Liver Physiol., 317, G824, 10.1152/ajpgi.00107.2019 · DOI
  67. Yokota, 2018, Lactobacillus plantarum AN1 cells increase caecal L. reuteri in an ICR mouse model of dextran sodium sulphate-induced inflammatory bowel disease, Int. Immunopharmacol., 56, 119, 10.1016/j.intimp.2018.01.020 · DOI
  68. Wang, 2018, Potential of Lactobacillus plantarum ZDY2013 and Bifidobacterium bifidum WBIN03 in relieving colitis by gut microbiota, immune, and anti-oxidative stress, Can. J. Microbiol., 64, 327, 10.1139/cjm-2017-0716 · DOI
  69. Yin, 2018, Bacteriocin biosynthesis contributes to the anti-inflammatory capacities of probiotic Lactobacillus plantarum, Benef. Microbes, 9, 333, 10.3920/BM2017.0096 · DOI
  70. Jang, 2019, Lactobacillus fermentum species ameliorate dextran sulfate sodium-induced colitis by regulating the immune response and altering gut microbiota, Gut Microbes, 10, 696, 10.1080/19490976.2019.1589281 · DOI
  71. Lai, H.H., Chiu, C.H., Kong, M.S., Chang, C.J., and Chen, C.C. (2019). Probiotic Lactobacillus casei: Effective for managing childhood diarrhea by altering gut microbiota and attenuating fecal inflammatory markers. Nutrients, 11. · DOI
  72. Shadnoush, 2015, Effects of probiotics on gut microbiota in patients with inflammatory bowel disease: A double-blind, placebo-controlled clinical trial, Korean J. Gastroenterol., 65, 215, 10.4166/kjg.2015.65.4.215 · DOI
  73. Ishikawa, 2003, Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis, J. Am. Coll. Nutr., 22, 56, 10.1080/07315724.2003.10719276 · DOI · Paper page
  74. Ahmed, 2007, Impact of consumption of different levels of Bifidobacterium lactis HN019 on the intestinal microflora of elderly human subjects, J. Nutr. Health Aging, 11, 26
  75. Rossi, G., Pengo, G., Caldin, M., Palumbo Piccionello, A., Steiner, J.M., Cohen, N.D., Jergens, A.E., and Suchodolski, J.S. (2014). Comparison of microbiological, histological, and immunomodulatory parameters in response to treatment with either combination therapy with prednisone and metronidazole or probiotic VSL#3 strains in dogs with idiopathic inflammatory bowel disease. PLoS ONE, 9. · DOI · Paper page
  76. Le, 2018, Efficacy of Lactobacillus plantarum in prevention of inflammatory bowel disease, Toxicol. Rep., 5, 314, 10.1016/j.toxrep.2018.02.007 · DOI
  77. Chapman, 2006, VSL#3 probiotic mixture: a review of its use in chronic inflammatory bowel diseases, Drugs, 66, 1371, 10.2165/00003495-200666100-00006 · DOI
  78. Isidro, 2017, The probiotic VSL#3 modulates colonic macrophages, inflammation, and microflora in acute trinitrobenzene sulfonic acid colitis, J. Histochem. Cytochem., 65, 445, 10.1369/0022155417718542 · DOI
  79. Miele, 2009, Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis, Am. J. Gastroenterol., 104, 437, 10.1038/ajg.2008.118 · DOI · Paper page
  80. West, 2013, Butyrylated starch increases colonic butyrate concentration but has limited effects on immunity in healthy physically active individuals, Exerc. Immunol. Rev., 19, 102
  81. Blatchford, 2017, Consumption of kiwifruit capsules increases Faecalibacterium prausnitzii abundance in functionally constipated individuals: a randomised controlled human trial, J. Nutr. Sci., 6, e52, 10.1017/jns.2017.52 · DOI
  82. Karoui, S. (2012). Manipulation of Intestinal Flora as a Way to Treat Crohn’s Disease: The Role of Probiotics, Prebiotics and Antibiotics. Crohn’s Disease, IntechOpen. · DOI
  83. Jia, 2018, The clinical effects of probiotics for inflammatory bowel disease: A meta-analysis, Medicine, 97, e13792, 10.1097/MD.0000000000013792 · DOI

Cited by

Metadata

Authors
Stojanov, S., Berlec, A., & Štrukelj, B.
Venue
Microorganisms
Publisher
MDPI AG
Published
2020-11-01
Volume
8
Issue
11
Pages
1715
ISSN
2076-2607 (ISSN-L)
DOI
10.3390/microorganisms8111715
OpenAlex
W3096586635
Cited by
1,885
References
17
FWCI
101.17
Type
journal article
Language
en
Open access
gold
Licence
creativecommons.org/licenses/by/4.0/ (vor)
Funders
Javna Agencija za Raziskovalno Dejavnost RS (J4-9327, P4-0127)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.